The observed intrapatient heterogeneity of GRPR and PSMA suggests that future theranostics for primary prostate tumors may benefit from an approach in which GRPR- and PSMA-targeting radiopharmaceuticals are combined. The gene discussed is FOLH1; the disease is prostate neoplasm.